These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 36568384)
1. Comprehensive analysis of a novel cuproptosis-related lncRNA signature associated with prognosis and tumor matrix features to predict immunotherapy in soft tissue carcinoma. Liu B; Pang K; Feng C; Liu Z; Li C; Zhang H; Liu P; Li Z; He S; Tu C Front Genet; 2022; 13():1063057. PubMed ID: 36568384 [No Abstract] [Full Text] [Related]
2. Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients. Zhang F; Zhang R; Zong J; Hou Y; Zhou M; Yan Z; Li T; Gan W; Lv S; Yang L; Zeng Z; Zhao W; Yang M Front Immunol; 2023; 14():1279789. PubMed ID: 37928532 [TBL] [Abstract][Full Text] [Related]
3. Prediction of prognosis, immune infiltration, and personalized treatment of hepatocellular carcinoma by analysis of cuproptosis-related long noncoding RNAs and verification Li S; Zhu Z; Lu J; Cao W; Song F; Xiao C; Zhang P; He Z; Weng J; Xu J Front Oncol; 2023; 13():1159126. PubMed ID: 37746284 [TBL] [Abstract][Full Text] [Related]
4. Prognosis and personalized treatment prediction in lung adenocarcinoma: An Ma C; Li F; He Z; Zhao S; Yang Y; Gu Z Front Pharmacol; 2023; 14():1113808. PubMed ID: 36874011 [No Abstract] [Full Text] [Related]
5. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
6. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma. Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774 [TBL] [Abstract][Full Text] [Related]
7. Significance of cuproptosis-related lncRNA signature in LUAD prognosis and immunotherapy: A machine learning approach. Yang L; Cui Y; Liang L; Lin J Thorac Cancer; 2023 Jun; 14(16):1451-1466. PubMed ID: 37076991 [TBL] [Abstract][Full Text] [Related]
8. Cuproptosis-related lncRNAs predict the clinical outcome and immune characteristics of hepatocellular carcinoma. Zhu H; Mao F; Wang K; Feng J; Cheng S Front Genet; 2022; 13():972212. PubMed ID: 36212138 [TBL] [Abstract][Full Text] [Related]
9. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Xu M; Mu J; Wang J; Zhou Q; Wang J Front Oncol; 2022; 12():961213. PubMed ID: 35965536 [TBL] [Abstract][Full Text] [Related]
10. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L Front Genet; 2023; 14():1056000. PubMed ID: 36845390 [No Abstract] [Full Text] [Related]
11. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma. Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546 [TBL] [Abstract][Full Text] [Related]
12. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma. Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG Biochem Genet; 2024 Oct; 62(5):3439-3466. PubMed ID: 38108937 [TBL] [Abstract][Full Text] [Related]
13. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma. Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235 [TBL] [Abstract][Full Text] [Related]
14. Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis. Li H; Jiang H; Huang Z; Chen Z; Chen N Aging (Albany NY); 2023 Aug; 15(16):8325-8344. PubMed ID: 37616061 [TBL] [Abstract][Full Text] [Related]
15. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer. Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429 [TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma. Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979 [TBL] [Abstract][Full Text] [Related]
17. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia. Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F Front Oncol; 2022; 12():966920. PubMed ID: 36276132 [TBL] [Abstract][Full Text] [Related]
18. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients. Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma. Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H Front Immunol; 2022; 13():991604. PubMed ID: 36685508 [TBL] [Abstract][Full Text] [Related]
20. Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis. Yin C; Gao M; Wang Q; Li H Comput Math Methods Med; 2023; 2023():6354212. PubMed ID: 36820319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]